Edgar Filing: Horizon Pharma plc - Form 4

Horizon Pha	rma plc											
Form 4	2 2014											
September 22, 2014									OMB APPROVAL			
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							COMMISSION	OMB Number:			
subject to Section 16. SECURITIES						burden hou response	Estimated average burden hours per response 0.5					
(Print or Type I	Responses)											
1. Name and Address of Reporting Person <u>*</u> Walbert Timothy P			2. Issuer Name and Ticker or Trading Symbol Horizon Pharma plc [HZNP]						5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of		-	-	. 1		(Chec	k all applicable	;)	
C/O HORIZ	ZON PHARMA LAIDE CHAME	. ,	(Month/E 09/19/2	ay/Year)					_X_ Director _X_ Officer (give below) Chairman		o Owner er (specify CEO	
Filed(M				f Amendment, Date Original d(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
DUBLIN, L	.2 8								Person		1 0	
(City)	(State)	(Zip)	Tabl	e I - Non	-De	erivative Se	ecuriti	es Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	 Executio any 		3. Transac Code (Instr. 8 Code	tion	4. Securitie (A) or Disp (Instr. 3, 4 Amount	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Ordinary Shares	09/19/2014			A <u>(1)</u>		164,060	А	<u>(1)</u>	164,060	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration I (Month/Day or D)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (Date Exercisable	Expiration Date	Title	Amount o Number o Shares	
Stock Option (Right to Buy)	\$ 10.43	09/19/2014		A <u>(1)</u>	121,701	(2)	07/15/2018	Ordinary Shares	121,70	
Stock Option (Right to Buy)	\$ 5.2	09/19/2014		A <u>(1)</u>	128,937	(2)	02/02/2020	Ordinary Shares	128,93′	
Stock Option (Right to Buy)	\$ 12.94	09/19/2014		A <u>(1)</u>	112,787	(2)	06/15/2020	Ordinary Shares	112,78′	
Stock Option (Right to Buy)	\$ 4.96	09/19/2014		A <u>(1)</u>	216,955	<u>(4)</u>	12/07/2021	Ordinary Shares	216,95:	
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	66,421	<u>(6)</u>	(5)	Ordinary Shares	66,421	
Stock Option (Right to Buy)	\$ 2.4	09/19/2014		A <u>(1)</u>	147,000	<u>(4)</u>	01/01/2023	Ordinary Shares	147,000	
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	96,525	<u>(6)</u>	(5)	Ordinary Shares	96,525	
Stock Option (Right to Buy)	\$ 7.61	09/19/2014		A <u>(1)</u>	223,000	<u>(4)</u>	01/01/2024	Ordinary Shares	223,000	
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <u>(1)</u>	198,000	<u>(6)</u>	(5)	Ordinary Shares	198,000	

Edgar Filing: Horizon Pharma plc - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Walbert Timothy P C/O HORIZON PHARMA PLC ADELAIDE CHAMBERS, PETER STREET DUBLIN, L2 8	г X		Chairman, President and CEO				
Signatures							
/s/ Paul W. Hoelscher, Attorney-in-Fact	09/22/2014						
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquisition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc., Vidara Therapeutics Holdings LLC, the Issuer (formerly known as Vidara Therapeutics International Ltd.),

- (1) Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of Horizon Pharma, Inc. are being canceled and automatically converted into securities of the Issuer. The Reporting Person's disposition of securities of Horizon Pharma, Inc. in the Merger will be reported on a separate Form 4.
- (2) The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.
- (3) In connection with the Merger, the stock option originally granted by Horizon Pharma, Inc. has been converted into an option to purchase the same number of ordinary shares of the Issuer at the same exercise price and on substantially the same terms.
- (4) The stock option vests in 48 equal monthly installments following the date of grant.
- (5) Each restricted stock unit represented a contingent right to receive one share of Horizon Pharma, Inc. common stock. Each restricted stock unit has been converted into a contingent right to receive one ordinary share of the Issuer.
- (6) The restricted stock units vest in four equal annual installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.